To the Editor: The study by Lintzeris and colleagues1 and the associated editorial2 criticise naltrexone implants. However, the study is replete with errors regarding the 12 cases reported.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- Genesis Medical Centre, Melbourne, VIC.
Correspondence: kozzy@genesismedical.com.au
- 1. Lintzeris N, Lee S, Scopelliti L, et al. Unplanned admissions to two Sydney public hospitals after naltrexone implants. Med J Aust 2008; 188: 441-444. <MJA full text>
- 2. Wodak AD, Ali R, Henry D, Sansom L. Ensuring the safety of new medications and devices: are naltrexone implants safe [editorial]? Med J Aust 2008; 188: 438-439. <MJA full text>
- 3. Bell JR, Young MR, Masterman SC, et al. A pilot study of naltrexone-accelerated detoxification in opioid dependence. Med J Aust 1999; 171: 26-30. <MJA full text>
- 4. Ali R, McGregor C, White J, et al. Randomised clinical trial of heroin withdrawal under anaesthetic prior to induction onto naltrexone maintenance therapy: outcomes at six months. Australian Professional Society on Alcohol and other Drugs Conference; 2000 Nov; Sydney, Australia.
- 5. Product information: ReVia. Melbourne: Bristol-Myers Squibb Australia, 2002.
Online responses are no longer available. Please refer to our instructions for authors page for more information.